Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance in Q3 2025 showed significant improvement, with revenue of 462 million yuan, a year-on-year increase of 2.56% and a quarter-on-quarter increase of 5.72%. The net profit attributable to the parent company was 94 million yuan, representing a year-on-year growth of 5.89% and a quarter-on-quarter growth of 51.61%. This improvement is attributed to the gradual recovery of conventional businesses such as home ventilators and cochlear implants [2][10]. - The second growth curve is accelerating, with the insulin pen now in mass production and continuous glucose monitoring (CGM) beginning bulk deliveries. The blood glucose product line is expected to enter a growth phase next year [2][10]. - The company's global production capacity is deepening, with significant progress in the construction and operation of its production base in Malaysia. The third phase of the industrial base is expected to be operational by the end of 2025, enhancing the company's global supply chain network [2][10]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.194 billion yuan, a year-on-year increase of 3.28%. The net profit attributable to the parent company was 208 million yuan, a year-on-year decrease of 19.25% [6]. - In Q3 2025, the company's gross margin was 42.24%, an increase of 5.91 percentage points from Q2 2025, while the net margin was 20.34%, up 6.06 percentage points from Q2 2025 [10]. Growth Prospects - The company is expanding its medical product components into core areas such as monitoring, respiratory therapy, emergency care, disinfection, and cardiovascular fields. Collaborations with global companies are underway in blood glucose management, in vitro diagnostics, electrophysiology, surgical robotics, and ophthalmic instruments [10]. - Revenue forecasts for 2025-2027 are projected at 1.833 billion, 2.163 billion, and 2.596 billion yuan, with net profits of 399 million, 479 million, and 582 million yuan, respectively [10].